The health care market is failing to support new antibiotics used to treat some of the world’s most dangerous, drug-resistant “superbugs,” according to a new analysis by University of Pittsburgh School of Medicine infectious disease scientists.
In a study published today in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology, investigators used nationwide prescription data to determine that the current annual U.S. sales of new antibiotics to treat carbapenem-resistant Enterobacteriaceae (CRE), one of the world’s most insidious drug-resistant bacteria, is about $101 million annually — significantly short of the $1 billion believed to be necessary to assure the financial viability of a new antibiotic. Even if new anti-CRE agents were used as widely as possible to treat CRE infections, the projected market size is only $289 million.
“New drugs against CRE address a major, previously unmet medical need and are critical to save lives. If the market can’t support them, then that is a chilling commentary on the future of antibiotic development,” said lead author Cornelius J. Clancy, M.D., associate professor of medicine and director of the mycology program and Extensively Drug Resistant Pathogen Laboratory in Pitt’s Division of Infectious Diseases. “Without antibiotics against increasingly resistant bacteria and fungi, much of modern medicine may become infeasible, including cancer chemotherapies, organ transplantation and high-risk abdominal surgeries.”
CRE infections are estimated to cause 1.5 to 4.5 million hospitalizations worldwide each year. The Centers for Disease Control and Prevention has classified CRE as urgent threat pathogens and calls them the “nightmare bacteria.” The World Health Organization and Infectious Disease Society of America have designated CRE as highest priority pathogens for development of new antibiotics.
Since 2015, five antibiotics against CRE have gained U.S. Food and Drug Administration approval and trials have so far shown three of them to be more effective and less toxic than the previous first-line antibiotics. One of the developers of the new anti-CRE drugs — the biopharmaceutical company Achaogen — declared bankruptcy in April because of its steep losses.
After reporting earlier this year that new CRE antibiotics are being prescribed in only about a quarter of infections that warrant them, Clancy and senior author M. Hong Nguyen, M.D., Pitt professor of medicine and director of UPMC’s Antimicrobial Management Program, investigated the market needed to make antibiotic development sustainable. They found a shortfall in revenue potential, evidenced by the financial difficulties faced by drug companies that created the new anti-CRE drugs.
“The prudent approach when fighting bacteria is to have multiple treatment options in the pipeline so that when resistance is inevitably developed to the current drug, a new antibiotic is waiting in the wings,” said Nguyen. “But we found that market prospects will become even more daunting if more anti-CRE drugs are approved, which is bad news for infectious disease physicians and, more importantly, our patients.”
Clancy and Nguyen propose a combination of “push” and “pull” incentives to encourage sustainable antibiotic development, starting with approval of the bilateral DISARM Act, which currently is under consideration in Congress. DISARM would assure full Centers for Medicare and Medicaid Services reimbursement for use of new antibiotics against resistant infections in hospitalized patients, rather than subsuming antibiotic costs into the discounted bundled payment hospitals receive. This would remove the disincentive hospitals face in using more effective but more expensive new agents rather than cheaper, older agents.
There also needs to be a cultural and behavioral change among hospitals and clinicians to encourage faster adoption and appropriate use of new antibiotics, the researchers said. Infectious disease physicians and pharmacists need to take responsibility for educating the wider clinical community about the importance of quickly updating and following guidelines on the best possible antibiotics to be using for their patients.
The Latest on: The future of antibiotics
via Google News
The Latest on: The future of antibiotics
- Macrolide Antibiotics Market Upcoming Key Events & Latest Innovations in the Industry By 2026on February 16, 2020 at 10:39 pm
Ameco Research added new research report to its vast database titled "Global Macrolide Antibiotics Market 2020" which provides extensive and highly detailed information on the key markets. This report ...
- UNR Researchers Aim To Stop The Spread Of Bacteria By Disrupting Communicationon February 12, 2020 at 5:42 am
Traditionally, antibiotics are used to fight bacterial pneumonia ... He explains how the new approach works and what it could mean for treatment of bacterial infections in the future. Yftah Tal-Gan, ...
- Combination of two antibiotics found to be no better than one for treating MRSA blood infectionson February 11, 2020 at 1:41 pm
Many laboratory studies have shown that combining vancomycin with a penicillin-class antibiotic results in improved killing of MRSA ... said this was a significant finding in the future treatment of ...
- MRSA Antibiotics Market Future Innovation Strategies by 2029 | Pfizer, Sanofi, Novartison February 11, 2020 at 2:16 am
Global News of MRSA Antibiotics Market Study 2020-2029, by Segment (Vancomycin, Teicoplanin, Linezolid, Cubicin), Playing a Pivotal Role in Expanding by (Adults, Children), Investment Analysis by ...
- ContraFect Announces Oral Presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)on February 10, 2020 at 10:54 am
We believe that the properties of our lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms ... “estimates,” “intends,” “plans,” “potential,” “promise” or ...
- Antibiotics Market to Discern Magnified Growth of 4.8% CAGR During 2019-2025on February 9, 2020 at 11:44 pm
Antibiotics Market Segmentation The global antibiotics market has been segmented ... PLC (UK), Sanofi (France), Bayer AG (Germany), Eli Lilly and Company (US), and Merck & Co., Inc. (US). At Market ...
- BRIEF-Navamedic Buys Marketing Authorisations For Antibiotics In The Nordicson February 7, 2020 at 4:19 am
* ENTERED INTO A TERM SHEET WITH ACS DOBFAR AND INFORLIFE TO ACQUIRE MARKETING AUTHORISATIONS FOR A SERIES OF ANTIBIOTICS FOR HOSPITAL USE IN NORDIC REGION * AS PART OF COLLABORATION, PARTIES HAVE AGR ...
- 'The future is microingredients' Discovery at Diamond V led Cargill to work with Goopon February 4, 2020 at 7:13 pm
“The future is microingredients,” David MacLennan ... Diamond V’s animal supplements help balance the microbiome — or bacteria in the gut — with the long-term goal of reducing dependence on ...
- Antitumor Antibiotic Market Size, Market Status and Future Forecasts to 2026on January 21, 2020 at 12:41 am
Reasons to Purchase the Report: To analyze the latest trends and patterns, as well as the future perspectives and key dynamics of the global Antitumor Antibiotic market. To study the factors that ...
- Aerosolized Antibiotics in Cystic Fibrosis: Current and Future Trendson January 20, 2020 at 4:00 pm
Chronic bacterial infection is one of the key challenges in caring for patients with cystic fibrosis (CF). Effective infection control requires appropriate administration of antibiotics.
via Bing News